State Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

State Street Corp increased its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 21.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 1,175,353 shares of the company’s stock after buying an additional 211,452 shares during the quarter. State Street Corp owned 3.22% of iTeos Therapeutics worth $12,000,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. nVerses Capital LLC grew its position in shares of iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after acquiring an additional 1,700 shares during the period. Point72 DIFC Ltd bought a new position in iTeos Therapeutics during the third quarter valued at $31,000. China Universal Asset Management Co. Ltd. raised its stake in shares of iTeos Therapeutics by 60.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after buying an additional 2,646 shares during the period. Quest Partners LLC raised its stake in shares of iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after buying an additional 9,934 shares during the period. Finally, US Bancorp DE increased its holdings in iTeos Therapeutics by 206.0% in the 3rd quarter. US Bancorp DE now owns 12,076 shares of the company’s stock worth $123,000 after acquiring an additional 8,129 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

Insider Buying and Selling

In related news, CFO Matthew Gall purchased 5,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was acquired at an average price of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 12.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wells Fargo & Company dropped their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a report on Friday, December 13th.

iTeos Therapeutics Trading Up 1.6 %

Shares of NASDAQ:ITOS opened at $7.47 on Thursday. iTeos Therapeutics, Inc. has a 12 month low of $7.09 and a 12 month high of $18.75. The stock has a market cap of $272.91 million, a P/E ratio of -2.37 and a beta of 1.37. The company has a 50 day moving average of $8.41 and a 200 day moving average of $12.42.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. On average, equities analysts forecast that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.